Chugai Pharmaceutical Co Ltd
4519: XTKS (JPN)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
¥3,169.00 | Bxtdnjz | Tfcjykd |
Chugai Earnings: Results in Line, Upbeat Guidance for 2024, Fair Value Estimate Increased
Narrow-moat Chugai’s full-year earnings were in line with expectations. Full-year revenue was JPY 1.11 trillion and operating profit margin was 36.9%. We've increased our fair value estimate to JPY 5,200 per share from JPY 4,860 due to incrementally higher forecasts for its hemophilia franchise, and we now view shares as fairly valued.